kynurenine has been researched along with MS (Multiple Sclerosis) in 30 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine acute (single-bout) and training effects of high-intensity interval training (HIIT) vs standard exercise therapy (moderate continuous training [MCT]) on plasma neurofilament light chain (pNfL) and kynurenine (KYN) pathway of tryptophan degradation metabolites in persons with multiple sclerosis (pwMS)." | 9.41 | Exercise Diminishes Plasma Neurofilament Light Chain and Reroutes the Kynurenine Pathway in Multiple Sclerosis. ( Bansi, J; Bittner, S; Bloch, W; Gonzenbach, R; Joisten, N; Knoop, A; Kool, J; Proschinger, S; Rademacher, A; Schenk, A; Steffen, F; Thevis, M; Walzik, D; Warnke, C; Zimmer, P, 2021) |
| "Melatonin (MT), a neurohormone with immunomodulatory properties, is one of the metabolites produced in the brain from tryptophan (TRP) that has already strong links with the neuropathogenesis of Multiple sclerosis (MS)." | 8.12 | Melatonin ameliorates disease severity in a mouse model of multiple sclerosis by modulating the kynurenine pathway. ( Ejtemaei-Mehr, S; Ghahremani, MH; Ghanbari, A; Ghazi-Khansari, M; Guillemin, GJ; Jand, Y, 2022) |
| "The excitotoxin quinolinic acid, a by-product of the kynurenine pathway, is known to be involved in several neurological diseases including multiple sclerosis (MS)." | 7.80 | Quinolinic acid toxicity on oligodendroglial cells: relevance for multiple sclerosis and therapeutic strategies. ( Adams, S; Brew, BJ; Guillemin, GJ; Jones, SP; Lim, CK; Sundaram, G, 2014) |
| "Although all PPARs ameliorate experimental autoimmune encephalomyelitis (EAE), recent evidence suggests that PPARα, PPARβ/δ agonists have less pronounced immunomodulatory effects and, along with PGC-1α, are not biomarkers of neuroinflammation in contrast to PPARγ." | 6.61 | Exploiting the Therapeutic Potential of Endogenous Immunomodulatory Systems in Multiple Sclerosis-Special Focus on the Peroxisome Proliferator-Activated Receptors (PPARs) and the Kynurenines. ( Fakan, B; Szalardy, L; Vecsei, L, 2019) |
| "The kynurenine pathway has been implicated in both the physiological processes of the central nervous system and in the pathomechanism of several neurological disorders as well." | 6.58 | Kynurenine System and Multiple Sclerosis, Pathomechanism and Drug Targets with An Emphasis on Laquinimod. ( Annus, A; Majlath, Z; Vecsei, L, 2018) |
| "The kynurenine pathway is a promising novel target via which to influence the immune system and to achieve neuroprotection, and further research is therefore needed with the aim of developing novel drugs for the treatment of multiple sclerosis and other autoimmune diseases." | 6.52 | Kynurenines and Multiple Sclerosis: The Dialogue between the Immune System and the Central Nervous System. ( Majláth, Z; Pukoli, D; Rajda, C; Vécsei, L, 2015) |
| " Three potential therapeutic strategies could be feasible to develop drugs to live up to expectations: (1) chemically related drugs with better bioavailability and higher affinity to the binding sites of excitatory receptors; (2) prodrugs of KYNA, which easily cross the blood-brain barrier combined with an inhibitor of organic acid transport for enhancement of the brain KYNA concentration; (3) inhibitors of enzymes of the kynurenine pathway." | 6.48 | The role of kynurenines in the pathomechanism of amyotrophic lateral sclerosis and multiple sclerosis: therapeutic implications. ( Bencsik, K; Füvesi, J; Rajda, C; Toldi, J; Vécsei, L, 2012) |
| "Neopterin is a biomarker for inflammation produced by macrophages." | 5.56 | Cerebrospinal Fluid Neurofilament Light Chain Is Associated with Kynurenine Pathway Metabolite Changes in Multiple Sclerosis. ( Babarczy, K; Galla, Z; Maróti, Z; Polyák, H; Pukoli, D; Rajda, C; Vécsei, L, 2020) |
| "To examine acute (single-bout) and training effects of high-intensity interval training (HIIT) vs standard exercise therapy (moderate continuous training [MCT]) on plasma neurofilament light chain (pNfL) and kynurenine (KYN) pathway of tryptophan degradation metabolites in persons with multiple sclerosis (pwMS)." | 5.41 | Exercise Diminishes Plasma Neurofilament Light Chain and Reroutes the Kynurenine Pathway in Multiple Sclerosis. ( Bansi, J; Bittner, S; Bloch, W; Gonzenbach, R; Joisten, N; Knoop, A; Kool, J; Proschinger, S; Rademacher, A; Schenk, A; Steffen, F; Thevis, M; Walzik, D; Warnke, C; Zimmer, P, 2021) |
| "Melatonin (MT), a neurohormone with immunomodulatory properties, is one of the metabolites produced in the brain from tryptophan (TRP) that has already strong links with the neuropathogenesis of Multiple sclerosis (MS)." | 4.12 | Melatonin ameliorates disease severity in a mouse model of multiple sclerosis by modulating the kynurenine pathway. ( Ejtemaei-Mehr, S; Ghahremani, MH; Ghanbari, A; Ghazi-Khansari, M; Guillemin, GJ; Jand, Y, 2022) |
| "To determine whether the metabolites of Kynurenine pathway (KP) could serve as biomarkers for distinguishing between viral CNS infections and autoimmune neuroinflammatory diseases, especially anti-N-methyl-D-aspartate receptor encephalitis (NMDARE) and herpes virus encephalitis (HSE)." | 4.02 | Differentiation of viral and autoimmune central nervous system inflammation by kynurenine pathway. ( Luo, Y; Möhn, N; Peßler, F; Senel, M; Skripuletz, T; Stangel, M; Sühs, KW; Tumani, H, 2021) |
| "The excitotoxin quinolinic acid, a by-product of the kynurenine pathway, is known to be involved in several neurological diseases including multiple sclerosis (MS)." | 3.80 | Quinolinic acid toxicity on oligodendroglial cells: relevance for multiple sclerosis and therapeutic strategies. ( Adams, S; Brew, BJ; Guillemin, GJ; Jones, SP; Lim, CK; Sundaram, G, 2014) |
| "Although all PPARs ameliorate experimental autoimmune encephalomyelitis (EAE), recent evidence suggests that PPARα, PPARβ/δ agonists have less pronounced immunomodulatory effects and, along with PGC-1α, are not biomarkers of neuroinflammation in contrast to PPARγ." | 2.61 | Exploiting the Therapeutic Potential of Endogenous Immunomodulatory Systems in Multiple Sclerosis-Special Focus on the Peroxisome Proliferator-Activated Receptors (PPARs) and the Kynurenines. ( Fakan, B; Szalardy, L; Vecsei, L, 2019) |
| "The kynurenine pathway has been implicated in both the physiological processes of the central nervous system and in the pathomechanism of several neurological disorders as well." | 2.58 | Kynurenine System and Multiple Sclerosis, Pathomechanism and Drug Targets with An Emphasis on Laquinimod. ( Annus, A; Majlath, Z; Vecsei, L, 2018) |
| "The kynurenine pathway is a promising novel target via which to influence the immune system and to achieve neuroprotection, and further research is therefore needed with the aim of developing novel drugs for the treatment of multiple sclerosis and other autoimmune diseases." | 2.52 | Kynurenines and Multiple Sclerosis: The Dialogue between the Immune System and the Central Nervous System. ( Majláth, Z; Pukoli, D; Rajda, C; Vécsei, L, 2015) |
| " Three potential therapeutic strategies could be feasible to develop drugs to live up to expectations: (1) chemically related drugs with better bioavailability and higher affinity to the binding sites of excitatory receptors; (2) prodrugs of KYNA, which easily cross the blood-brain barrier combined with an inhibitor of organic acid transport for enhancement of the brain KYNA concentration; (3) inhibitors of enzymes of the kynurenine pathway." | 2.48 | The role of kynurenines in the pathomechanism of amyotrophic lateral sclerosis and multiple sclerosis: therapeutic implications. ( Bencsik, K; Füvesi, J; Rajda, C; Toldi, J; Vécsei, L, 2012) |
| "Neopterin is a biomarker for inflammation produced by macrophages." | 1.56 | Cerebrospinal Fluid Neurofilament Light Chain Is Associated with Kynurenine Pathway Metabolite Changes in Multiple Sclerosis. ( Babarczy, K; Galla, Z; Maróti, Z; Polyák, H; Pukoli, D; Rajda, C; Vécsei, L, 2020) |
| "In patients with encephalopathy, serum QUIN was elevated with corresponding increments in CSF QUIN." | 1.28 | Neuroactive kynurenines in Lyme borreliosis. ( Halperin, JJ; Heyes, MP, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (6.67) | 18.2507 |
| 2000's | 7 (23.33) | 29.6817 |
| 2010's | 9 (30.00) | 24.3611 |
| 2020's | 12 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Luo, Y | 1 |
| Möhn, N | 1 |
| Skripuletz, T | 1 |
| Senel, M | 1 |
| Tumani, H | 1 |
| Peßler, F | 1 |
| Sühs, KW | 1 |
| Stangel, M | 1 |
| Saraste, M | 1 |
| Matilainen, M | 1 |
| Rajda, C | 5 |
| Galla, Z | 2 |
| Sucksdorff, M | 1 |
| Vécsei, L | 12 |
| Airas, L | 1 |
| Jand, Y | 1 |
| Ghahremani, MH | 1 |
| Ghanbari, A | 1 |
| Ejtemaei-Mehr, S | 1 |
| Guillemin, GJ | 4 |
| Ghazi-Khansari, M | 1 |
| Fathi, M | 3 |
| Vakili, K | 3 |
| Yaghoobpoor, S | 3 |
| Tavasol, A | 3 |
| Jazi, K | 3 |
| Mohamadkhani, A | 3 |
| Klegeris, A | 3 |
| McElhinney, A | 3 |
| Mafi, Z | 3 |
| Hajiesmaeili, M | 3 |
| Sayehmiri, F | 3 |
| Isık, SMT | 1 |
| Onmaz, DE | 1 |
| Ekmekci, AH | 1 |
| Ozturk, S | 1 |
| Unlu, A | 1 |
| Abusoglu, S | 1 |
| Mondanelli, G | 2 |
| Coletti, A | 1 |
| Greco, FA | 1 |
| Pallotta, MT | 1 |
| Orabona, C | 1 |
| Iacono, A | 1 |
| Belladonna, ML | 1 |
| Albini, E | 1 |
| Panfili, E | 1 |
| Fallarino, F | 1 |
| Gargaro, M | 1 |
| Manni, G | 1 |
| Matino, D | 1 |
| Carvalho, A | 1 |
| Cunha, C | 1 |
| Maciel, P | 1 |
| Di Filippo, M | 2 |
| Gaetani, L | 2 |
| Bianchi, R | 1 |
| Vacca, C | 1 |
| Iamandii, IM | 1 |
| Proietti, E | 2 |
| Boscia, F | 1 |
| Annunziato, L | 1 |
| Peppelenbosch, M | 1 |
| Puccetti, P | 1 |
| Calabresi, P | 2 |
| Macchiarulo, A | 1 |
| Santambrogio, L | 1 |
| Volpi, C | 1 |
| Grohmann, U | 2 |
| Boscaro, F | 1 |
| Pieraccini, G | 1 |
| Romani, L | 1 |
| Zelante, T | 1 |
| Polyák, H | 1 |
| Maróti, Z | 1 |
| Babarczy, K | 1 |
| Pukoli, D | 2 |
| Biernacki, T | 1 |
| Sandi, D | 2 |
| Bencsik, K | 3 |
| Rossini, S | 1 |
| Joisten, N | 1 |
| Rademacher, A | 1 |
| Warnke, C | 1 |
| Proschinger, S | 1 |
| Schenk, A | 1 |
| Walzik, D | 1 |
| Knoop, A | 1 |
| Thevis, M | 1 |
| Steffen, F | 1 |
| Bittner, S | 1 |
| Gonzenbach, R | 1 |
| Kool, J | 1 |
| Bloch, W | 1 |
| Bansi, J | 1 |
| Zimmer, P | 1 |
| Fricska-Nagy, Z | 1 |
| Fakan, B | 1 |
| Szalardy, L | 1 |
| Sadowska-Bartosz, I | 1 |
| Adamczyk-Sowa, M | 1 |
| Gajewska, A | 1 |
| Bartosz, G | 1 |
| Sundaram, G | 1 |
| Brew, BJ | 3 |
| Jones, SP | 1 |
| Adams, S | 1 |
| Lim, CK | 2 |
| Aeinehband, S | 1 |
| Brenner, P | 1 |
| Ståhl, S | 1 |
| Bhat, M | 1 |
| Fidock, MD | 1 |
| Khademi, M | 1 |
| Olsson, T | 1 |
| Engberg, G | 1 |
| Jokinen, J | 1 |
| Erhardt, S | 1 |
| Piehl, F | 1 |
| Majláth, Z | 2 |
| Annus, A | 1 |
| Bilgin, A | 1 |
| Lovejoy, DB | 1 |
| Tan, V | 1 |
| Bustamante, S | 1 |
| Taylor, BV | 1 |
| Bessede, A | 1 |
| Vamos, E | 1 |
| Pardutz, A | 1 |
| Klivenyi, P | 3 |
| Toldi, J | 3 |
| Durastanti, V | 1 |
| Lugaresi, A | 1 |
| Bramanti, P | 1 |
| Amato, M | 1 |
| Bellantonio, P | 1 |
| De Luca, G | 1 |
| Picconi, O | 1 |
| Fantozzi, R | 1 |
| Locatelli, L | 1 |
| Solda', A | 1 |
| Sessa, E | 1 |
| Totaro, R | 1 |
| Marino, S | 1 |
| Zipoli, V | 1 |
| Zorzon, M | 1 |
| Millefiorini, E | 1 |
| Füvesi, J | 1 |
| Hartai, Z | 1 |
| Janaky, T | 1 |
| Penke, B | 1 |
| Dux, L | 1 |
| Kwidzinski, E | 1 |
| Bechmann, I | 1 |
| Bergquist, J | 1 |
| Rudzite, V | 1 |
| Berzinsh, J | 1 |
| Grivane, I | 1 |
| Fuchs, D | 1 |
| Baier-Bitterlich, G | 1 |
| Wachter, H | 1 |
| Chiarugi, A | 1 |
| Cozzi, A | 1 |
| Ballerini, C | 1 |
| Massacesi, L | 1 |
| Moroni, F | 1 |
| Kerr, SJ | 1 |
| Pemberton, LA | 1 |
| Smith, DG | 1 |
| Smythe, GA | 1 |
| Armati, PJ | 1 |
| Halperin, JJ | 1 |
| Heyes, MP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Influence of High-Intensity Interval Training Compared to Moderate Continuous Training on Cardiorespiratory Fitness, Symptom Improvement, and Disease-specific Biomarkers in Primary Progressive Multiple Sclerosis[NCT05229861] | 61 participants (Anticipated) | Interventional | 2022-05-10 | Recruiting | |||
| Influence of Different Rehabilitative Aerobic Exercise Programs on (Anti-) Inflammatory Immune Signalling, Cognitive Performance and Processing Skills in Persons With MS - A Randomized Controlled Trial[NCT03652519] | 72 participants (Actual) | Interventional | 2018-11-21 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for kynurenine and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Topics: Humans; Kynurenic Acid; Kynurenine; Leukocytes, Mononuclear; Multiple Sclerosis; Quinolinic Acid; Tr | 2022 |
Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Topics: Humans; Kynurenic Acid; Kynurenine; Leukocytes, Mononuclear; Multiple Sclerosis; Quinolinic Acid; Tr | 2022 |
Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Topics: Humans; Kynurenic Acid; Kynurenine; Leukocytes, Mononuclear; Multiple Sclerosis; Quinolinic Acid; Tr | 2022 |
Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Topics: Humans; Kynurenic Acid; Kynurenine; Leukocytes, Mononuclear; Multiple Sclerosis; Quinolinic Acid; Tr | 2022 |
Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Topics: Humans; Kynurenic Acid; Kynurenine; Leukocytes, Mononuclear; Multiple Sclerosis; Quinolinic Acid; Tr | 2022 |
Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Topics: Humans; Kynurenic Acid; Kynurenine; Leukocytes, Mononuclear; Multiple Sclerosis; Quinolinic Acid; Tr | 2022 |
Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Topics: Humans; Kynurenic Acid; Kynurenine; Leukocytes, Mononuclear; Multiple Sclerosis; Quinolinic Acid; Tr | 2022 |
Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Topics: Humans; Kynurenic Acid; Kynurenine; Leukocytes, Mononuclear; Multiple Sclerosis; Quinolinic Acid; Tr | 2022 |
Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Topics: Humans; Kynurenic Acid; Kynurenine; Leukocytes, Mononuclear; Multiple Sclerosis; Quinolinic Acid; Tr | 2022 |
Kynurenines in the Pathogenesis of Multiple Sclerosis: Therapeutic Perspectives.
Topics: Humans; Kynurenine; Multiple Sclerosis | 2020 |
Polyamines and Kynurenines at the Intersection of Immune Modulation.
Topics: Animals; Autoimmune Diseases; Disease Models, Animal; Humans; Immunomodulation; Kynurenine; Multiple | 2020 |
Neurodegeneration in Multiple Sclerosis: Symptoms of Silent Progression, Biomarkers and Neuroprotective Therapy-Kynurenines Are Important Players.
Topics: Animals; Biomarkers; Disease Progression; Humans; Kynurenine; Molecular Targeted Therapy; Multiple S | 2021 |
Exploiting the Therapeutic Potential of Endogenous Immunomodulatory Systems in Multiple Sclerosis-Special Focus on the Peroxisome Proliferator-Activated Receptors (PPARs) and the Kynurenines.
Topics: Animals; Biomarkers; Encephalomyelitis, Autoimmune, Experimental; Humans; Immunologic Factors; Immun | 2019 |
Kynurenines and Multiple Sclerosis: The Dialogue between the Immune System and the Central Nervous System.
Topics: Animals; Central Nervous System; Disease Models, Animal; Humans; Immune System; Immunomodulation; Ky | 2015 |
Kynurenine System and Multiple Sclerosis, Pathomechanism and Drug Targets with An Emphasis on Laquinimod.
Topics: Animals; Brain; Disease Progression; Drug Development; Humans; Kynurenine; Molecular Targeted Therap | 2018 |
The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection.
Topics: Alzheimer Disease; Animals; Brain; Brain Diseases; Brain Ischemia; Epilepsy; Humans; Huntington Dise | 2009 |
The role of kynurenines in the pathomechanism of amyotrophic lateral sclerosis and multiple sclerosis: therapeutic implications.
Topics: Amyotrophic Lateral Sclerosis; Animals; Humans; Kynurenine; Multiple Sclerosis; Neural Pathways; Pro | 2012 |
Kynurenines in neurodegenerative disorders: therapeutic consideration.
Topics: AIDS Dementia Complex; Animals; Central Nervous System Diseases; Down Syndrome; Enzyme Inhibitors; H | 2004 |
IDO expression in the brain: a double-edged sword.
Topics: Animals; Brain; Candidiasis; Cytomegalovirus Infections; Encephalomyelitis, Autoimmune, Experimental | 2007 |
Kynurenines, redox disturbances and neurodegeneration in multiple sclerosis.
Topics: Animals; Antioxidants; Encephalomyelitis, Autoimmune, Experimental; Enzyme Inhibitors; Humans; Kynur | 2007 |
2 trials available for kynurenine and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Exercise Diminishes Plasma Neurofilament Light Chain and Reroutes the Kynurenine Pathway in Multiple Sclerosis.
Topics: Adult; Aged; Aged, 80 and over; Exercise; Exercise Therapy; Female; Humans; Kynurenine; Male; Middle | 2021 |
Exercise Diminishes Plasma Neurofilament Light Chain and Reroutes the Kynurenine Pathway in Multiple Sclerosis.
Topics: Adult; Aged; Aged, 80 and over; Exercise; Exercise Therapy; Female; Humans; Kynurenine; Male; Middle | 2021 |
Exercise Diminishes Plasma Neurofilament Light Chain and Reroutes the Kynurenine Pathway in Multiple Sclerosis.
Topics: Adult; Aged; Aged, 80 and over; Exercise; Exercise Therapy; Female; Humans; Kynurenine; Male; Middle | 2021 |
Exercise Diminishes Plasma Neurofilament Light Chain and Reroutes the Kynurenine Pathway in Multiple Sclerosis.
Topics: Adult; Aged; Aged, 80 and over; Exercise; Exercise Therapy; Female; Humans; Kynurenine; Male; Middle | 2021 |
Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients.
Topics: Adult; Antibodies, Neutralizing; Biomarkers; Demography; Dose-Response Relationship, Drug; Female; H | 2011 |
16 other studies available for kynurenine and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Differentiation of viral and autoimmune central nervous system inflammation by kynurenine pathway.
Topics: Adult; Aged; Aged, 80 and over; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Biomarkers; Encepha | 2021 |
Association between microglial activation and serum kynurenine pathway metabolites in multiple sclerosis patients.
Topics: Brain; Humans; Kynurenine; Microglia; Multiple Sclerosis; Receptors, GABA; White Matter | 2022 |
Melatonin ameliorates disease severity in a mouse model of multiple sclerosis by modulating the kynurenine pathway.
Topics: Animals; Biological Factors; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Hu | 2022 |
Relationship of tryptophan metabolites with the type and severity of multiple sclerosis.
Topics: Animals; Humans; Kynurenic Acid; Kynurenine; Mammals; Multiple Sclerosis; Quinolinic Acid; Tryptopha | 2023 |
Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation.
Topics: Allosteric Regulation; Allosteric Site; Animals; Biocatalysis; Disease Models, Animal; Encephalomyel | 2020 |
Host and Microbial Tryptophan Metabolic Profiling in Multiple Sclerosis.
Topics: Adult; Biomarkers; Female; Gastrointestinal Microbiome; Humans; Italy; Kynurenine; Male; Metabolomic | 2020 |
Cerebrospinal Fluid Neurofilament Light Chain Is Associated with Kynurenine Pathway Metabolite Changes in Multiple Sclerosis.
Topics: Biomarkers; Brain; Enzyme-Linked Immunosorbent Assay; Humans; Kynurenine; Mass Spectrometry; Metabol | 2020 |
Oxidative modification of blood serum proteins in multiple sclerosis after interferon or mitoxantrone treatment.
Topics: Adult; Advanced Oxidation Protein Products; Disability Evaluation; Female; Fructosamine; Glycophorin | 2014 |
Quinolinic acid toxicity on oligodendroglial cells: relevance for multiple sclerosis and therapeutic strategies.
Topics: Animals; Antibodies, Monoclonal; Cell Line; Cell Line, Transformed; Encephalomyelitis, Autoimmune, E | 2014 |
Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms.
Topics: Adult; Disease Progression; Female; Humans; Kynurenine; Male; Middle Aged; Multiple Sclerosis; Trypt | 2016 |
Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression.
Topics: Adult; Biomarkers; Cohort Studies; Computer Simulation; Demography; Disease Progression; Female; Fol | 2017 |
Kynurenine metabolism in multiple sclerosis.
Topics: Adolescent; Adult; Erythrocytes; Female; Humans; Kynurenic Acid; Kynurenine; Male; Middle Aged; Mult | 2005 |
Serum tryptophan, kynurenine, and neopterin in patients with Guillain-Barre-syndrome (GBS) and multiple sclerosis (MS).
Topics: Biopterins; Humans; Kynurenine; Multiple Sclerosis; Neopterin; Polyradiculoneuropathy; Reference Val | 1996 |
Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis.
Topics: Animals; Astrocytes; Brain; Cytoplasmic Granules; Disease Models, Animal; Encephalomyelitis, Autoimm | 2001 |
IFN-beta1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatment.
Topics: Cells, Cultured; Dose-Response Relationship, Drug; Humans; Interferon beta-1a; Interferon beta-1b; I | 2001 |
Neuroactive kynurenines in Lyme borreliosis.
Topics: Brain Diseases; Humans; Kynurenine; Lyme Disease; Lymphokines; Multiple Sclerosis; Nervous System Di | 1992 |